PR in the Philippines

PHILADELPHIA, PA, Aug 6, 2025 - (ACN Newswire via SeaPRwire.com) - TruMerit, a worldwide leader in international credentials evaluation to support health worker careers, today introduced the Certified Global Nurse (CGN), the world's first truly global credential for first-level, general nurses (RNs).TruMerit | Global careers. Care anywhere.The new, merit-based credential is available to any qualified nurse - from any country - to recognize their competencies, regardless of where they choose to live and work. It is awarded upon passage of TruMerit's Nurse Qualifying Exam (NQE), which applicants may take after verification of their nursing education and licensure.Previously known as the CGFNS Qualifying Exam and used by nurses migrating to the United States, the NQE was reinvented with a global focus to support the ongoing evolution of nursing practice worldwide and particularly the emergence of key challenges such as digital health, mental health, and climate change. This was achieved through a collaborative process involving more than 70 nursing experts from 50 countries, with all World Health Organization regions and World Bank country income levels represented. The experts agreed upon a core set of nursing practice standards after analyzing nursing competency frameworks from 37 countries.In addition to its role as a key requirement for the CGN credential, the upgraded exam continues to support other TruMerit programs - such as the VisaScreen® Visa Credentials Assessment Service and the Certification Program® - as a shared global framework for validating the applied knowledge and practice competence of nurses worldwide."The Certified Global Nurse credential offers nurses everywhere a common framework for meeting globally agreed-upon essential nursing practice standards," said Dr. Peter Preziosi, TruMerit's President and CEO. "When nurses carry the credential, their employers and colleagues will know that their applied nursing knowledge and skills are validated against a global benchmark, attesting to their qualifications for delivering quality healthcare."The credential is ultimately intended to provide nurses with greater mobility within the profession, within their native countries, and across geopolitical boundaries throughout their careers."By signifying work-readiness on an international scale, and thereby helping expand the pool of readily identifiable qualified nurses worldwide, global credentialing will become part of the solution to the challenges health systems are facing around the world," said Preziosi."We hope this credential can contribute to a sustained, collaborative effort involving many stakeholders-health ministries, international agencies, health systems, nursing schools, and nursing associations worldwide-to harmonize nursing education and practice and support the future growth of the global nursing workforce," he said.The Nurse Qualifying Exam is a proctored examination that will be offered four times a year at more than 1,000 Kryterion testing centers located around the world, with the first test window scheduled for November 10-14, 2025. Nurses who wish to earn a CGN credential and sit for the NQE in November must apply by September 30 at the TruMerit website, where they will find more information on the credential and how to prepare for the exam.The testing schedule for 2026 will be announced later this year.About TruMeritTruMerit is a worldwide leader in healthcare workforce development. Formerly known as CGFNS International, the organization has a nearly 50-year history supporting the career mobility of nurses and other healthcare workers - and those who license and hire them - by validating their education, skills, and experience as they seek authorization to practice in the United States and other countries. As TruMerit, this mission has been expanded to building workforce capacity that meets the needs of people in a rapidly evolving global health landscape. Through its Global Health Workforce Development Institute, the organization is advancing evidence-based research, thought leadership, and advocacy in support of healthcare workforce development solutions, including globally recognized practice standards and certifications that will enhance career pathways for healthcare workers. www.trumerit.orgContact InformationDavid St. Johndstjohn@trumerit.orgSOURCE: TruMerit Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 5, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) today announced that the supplemental application for the production expansion of NEFECON® has been officially approved by China’s National Medical Products Administration (NMPA). This approval for production expansion will further boost capacity and increase product supply, enabling a more efficient response to the growing clinical demand in China and across Asia.NEFECON® is the first and only etiological treatment for IgA nephropathy (IgAN) to receive full approval in China, the United States, and Europe, serving as a foundational first-line therapy for patients with IgAN. Since its initial approval in China in November 2023, NEFECON® was subsequently included in the National Reimbursement Drug List (NRDL) in November 2024, and received full approval from the NMPA in May 2025, irrespective of proteinuria levels, benefiting most individuals living with IgAN.NEFECON® specifically modulates the mucosal immune system in the gut to reduce the formation of pathogenic galactose-deficient IgA1 (Gd-IgA1) that trigger IgAN. Results from the Phase 3 clinical study NefIgArd demonstrated that NEFECON® reduces the decline in kidney function by 50%. Results from Phase 3 clinical study NefIgArd of the Chinese population shows that NEFECON® reduces kidney function decline by 66%, and delays disease progression to dialysis or kidney transplantation by 12.8 years.“The expansion of our NEFECON® production capacity will help better meet the growing clinical treatment needs of IgAN patients in China.” Said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “China has one of the highest rates of primary glomerular disease in the world, with more than 5 million patients estimated to be living with IgAN and over 100,000 new cases diagnosed each year. Chinese IgAN patients generally experience faster disease progression and poorer prognosis, highlighting a significant unmet medical need.As the only etiological treatment for IgAN currently recommended by both international and Chinese guidelines, the expansion of NEFECON® production will further accelerate the uptake of etiological treatment, enabling more patients to access standardized treatment earlier to delay disease progression and protect kidney function. We will continue to enhance the accessibility and affordability of NEFECON®, supporting its advancement from ‘changing the treatment landscape’ to ‘redefining the standard of care’.”NEFECON®, as the only in-disease IgAN treatment has been included in the KDIGO 2024 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (public review draft), making it the only targeted therapy endorsed by both international and Chinese guidelines. NEFECON® has been approved across all Everest Medicines’ territories, including mainland China, Hong Kong SAR, Macau SAR, Taiwan region, China, as well as Singapore and South Korea, and continues to expand its therapeutic impact across Asia.As production capacity continues to grow and supply capabilities improve, NEFECON® is well positioned to benefit a broader patient population by accelerating the uptake of etiological treatment, enabling more patients to access standardized care earlier to delay disease progression and preserve kidney function. Copyright 2025 ACN Newswire via SeaPRwire.com.

NEW YORK, Aug 4, 2025 - (ACN Newswire via SeaPRwire.com) - Traveler Care, a breakthrough medical dispatch platform that brings urgent care directly to travelers in hotels, Airbnbs, and vacation rentals, has officially launched worldwide - offering travel insurance companies a high-impact solution to reduce avoidable emergency room and hospital claims.Traveler care traveler.care home pageA Concierge Alternative to the Emergency RoomTraveler Care connects travel insurers and their policyholders to a network of licensed, on-call providers who visit travelers in their accommodations - typically within 60-90 minutes. Conditions such as flu, food poisoning, dehydration, allergic reactions, UTIs, sprains, and wound care are treated on-site, eliminating the need for an ER visit."In most cases, travelers just need a doctor - not a hospital admission," said Eli Ofel, founder of Traveler Care. "We've built a scalable, insurer-ready solution that saves money and delivers a far better traveler experience."Reduce Claims by $10,000+ Per VisitOn average, a non-emergency ER visit costs travel insurers $13,000 to $17,000. Traveler Care treats the same conditions in-room for $1,700 to $3,000 - including diagnostics like mobile X-ray, ultrasound, IV therapy, and wound treatment.Pilot results have shown:- 83% reduction in ER claim volume- $10,000+ savings per case avoided- Higher satisfaction scores among travelersBuilt for Travel Insurance PartnersTraveler Care is fully designed for insurance integration - with white-label and API options available for TPAs, underwriters, and global assistance networks.Platform features:- Nationwide U.S. coverage (with international expansion underway)- A robust dispatch network, for example companies like Leaa Health, Sickday, Heal, DocGo and more, any location that the travel insurance is experiencing high volume travel care will create a solution for that particular location within 60 days.- HIPAA-compliant documentation + one-click claims integration- Supports care delivery to hotels, Airbnbs, resorts, and serviced apartmentsNow Onboarding Insurance Companies Worldwide"We believe travel insurance companies shouldn't just pay for care - they should deliver it smarter," said Ofel. "With Traveler Care, you lower claims without compromising care."Insurance providers, TPAs, and global assistance companies are invited to partner and deploy in-room urgent care as part of their medical benefit stack.ContactTo schedule a private demo or receive our ROI case study:Visit www.traveler.careEmail: partners@traveler.carePhone: +1 (347) 733-0563About Eli OfelEli Ofel is a serial entrepreneur and visionary behind multiple AI- and tech-powered platforms in healthcare, finance, and transportation. He is the founder and CEO of Traveler Care, Run.Vet, Leaa Health, 02.Market, and Lender.Market. With over 20 years of experience in healthcare operations, insurance workflows, and mobile logistics, Ofel brings a proven ability to bridge patient needs with scalable platform solutions - saving time, money, and lives.Contact InformationEli OfelCEOeli@traveler.care3477330563SOURCE: Traveler care Copyright 2025 ACN Newswire via SeaPRwire.com.

Boca Raton, Florida--(ACN Newswire via SeaPRwire.com - August 4, 2025) - Atlas Lithium Corporation (NASDAQ: ATLX) ("Atlas Lithium" or "Company"), a leading lithium development company, is pleased to announce that SGS Canada Inc. ("SGS") has completed the Definitive Feasibility Study ("DFS") for the Company's 100%-owned Neves Lithium Project ("Project"), a technical report prepared under the U.S. guidelines of Item 1300 of Regulation S-K ("Regulation S-K 1300"). This hard-rock Project is well-suited to being a low-cost open-pit mining operation, as its spodumene deposits are located relatively close to the surface. Located in the state of Minas Gerais, Brazil, the Project encompasses 4 of the 98 mineral rights for lithium owned by Atlas Lithium. As detailed in the DFS, the Neves Project is expected to deliver strong financial metrics with an internal rate of return ("IRR") of 145%, payback in 11 months from the start of operations, and an after-tax net present value ("NPV") of $539 million. Importantly, the DFS estimates the Neves Project to have operational production costs of only $489 per tonne of lithium concentrate, positioning Atlas Lithium among the world's lowest-cost producers. Complete details of these metrics can be found in the DFS, filed with the Securities and Exchange Commission as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. Marc-Antoine Laporte from SGS serves as the Qualified Person for the DFS under Regulation S-K 1300. SGS is well-known as a global leader in testing, inspection, and certification services for mineral properties and projects.Industry-Leading Capital Efficiency and Low Operating CostsThe DFS supports that expected direct capital expenditures of $57.6 million will be needed for the implementation of the Project, by far the lowest such capital costs among other announced projects in Brazil. Notably, Atlas Lithium has already invested approximately $30 million in acquiring and transporting the Project's newly fabricated dense media separation ("DMS") plant to Brazil, as previously reported. The Company has secured two non-dilutive pre-payment agreements for its lithium concentrate totaling $40 million and has received additional funding interest from other parties, including 10-year debt financing options, any of which could support the Project's capital requirements.The Company believes that the DFS validates the Project's strong economics, positioning it among the most capital-efficient and lowest-cost hard-rock lithium developments globally. The Project will employ proven DMS technology, with comprehensive metallurgical testing demonstrating an expected robust lithium recovery rate of 61.7% to produce high-quality, low-impurity lithium concentrate. This relatively straightforward, low-risk DMS processing methodology minimizes technical complexity and operational risk while enabling a low environmental footprint.Atlas Lithium's mineral right to be mined, as detailed in the DFS, received its "Portaria de Lavra" (mining concession) status from Brazil's Ministry of Mines and Energy on May 27, 2025 — the highest level of titleship in Brazil and one that allows continuous mining operations. Multiple deposit areas within the Project remain open for resource expansion along strike and at depth and are thus expected to extend the life of mine. Additionally, numerous high-potential geological targets remain within the Project's mineral rights, providing compelling opportunities for future exploration.Located in the established Araçuaí Pegmatite District in the Vale do Jequitinhonha, often called Lithium Valley, the Project benefits from favorable infrastructure, including proximity to transportation networks, water resources, and skilled labor. The Project qualifies for tax incentives from the Superintendency for the Development of the Northeast (SUDENE), as promulgated by Brazil's Ministry of Integration and Regional Development, reducing the corporate tax rate from 34% to 15.25% and further enhancing profitability."The DFS indicates potentially outstanding returns for our initial vision of developing a focused, near-term, profitable lithium production asset with minimal capital requirements," said Marc Fogassa, Chairman and CEO of Atlas Lithium. "The combination of our low capital intensity and rapid payback period is expected to create exceptional value for our shareholders while positioning Atlas Lithium to benefit from future organic expansion opportunities at Neves and other high-potential lithium areas that we own. Importantly, we are creating many quality employment opportunities in the Vale do Jequitinhonha region, representing a significant societal contribution of our Project."Experienced Leadership Driving Project ImplementationFollowing his leadership role in collaborating with SGS on the DFS, project implementation activities are being supervised by Eduardo Queiroz, Atlas Lithium's Project Management Officer (PMO) and Vice President of Engineering. Mr. Queiroz has more than two decades of hands-on experience managing complex, large-scale mining projects."The DFS demonstrates the technical robustness of the Project, with proven DMS technology and comprehensive metallurgical test work validated by SGS, a premier firm in the lithium space," said Mr. Queiroz. "With our processing plant fully fabricated and paid for, and now with the DFS in hand, we have systematically de-risked the Project. I am excited to lead the implementation phase of Atlas Lithium's journey to becoming a lithium producer."Salinas and Clear: The Next Expansion FrontierAtlas Lithium is strategically positioned to capitalize on its extensive regional lithium exploration portfolio in Brazil, particularly through advancement of its Salinas Project and Clear Project, both 100% owned by the Company. Atlas Lithium's Salinas Project is just 5 miles east of the Colina lithium asset previously owned by Latin Resources — a major factor in Pilbara Minerals's acquisition of that company in 2024 for approximately $370 million. At the Salinas Project, Atlas Lithium has already achieved promising initial results, including the discovery of spodumene-rich pegmatites very close to the surface, and highly positive results from soil geochemistry and from LIDAR geological mapping.Atlas Lithium's Clear Project is located less than 4 miles from Sigma Lithium's operating lithium mine, and represents significant untapped potential with highly positive results from soil geochemistry and from LIDAR geological mapping.Diversification in Critical MineralsAtlas Lithium also owns approximately 30% of Atlas Critical Minerals Corporation (OTCQB: JUPGF), a separate company with exploration programs in uranium, rare earths, titanium, and graphite.About Atlas Lithium Corporation Atlas Lithium Corporation (NASDAQ: ATLX) is a lithium development company focused on advancing its Neves Project to production. The Neves Project's Definitive Feasibility Study demonstrates excellent economics with a 145% IRR, $539 million NPV, and an 11-month payback. The Neves Project has received operational permitting, and its dense media separation plant has been acquired and transported to Brazil. With approximately 539 square kilometers of lithium mineral rights, Atlas Lithium owns the largest lithium exploration footprint in Brazil among publicly listed companies. Additionally, Atlas Lithium currently holds an approximate 30% ownership stake in Atlas Critical Minerals Corporation (OTCQB: JUPGF).Safe Harbor StatementThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based upon the current plans, estimates and projections of Atlas Lithium and its subsidiaries and are subject to inherent risks and uncertainties which could cause actual results to differ from the forward-looking statements. Such statements include, among others, those concerning market and industry segment growth and demand and acceptance of new and existing products; any projections of production, reserves, sales, earnings, revenue, margins or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements regarding future economic conditions or performance; uncertainties related to conducting business in Brazil, as well as all assumptions, expectations, predictions, intentions or beliefs about future events. Therefore, you should not place undue reliance on these forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: Atlas Lithium's ability to successfully assemble and begin operations of its modular plant; reaching estimated production, development plans and cost estimates for the Neves Lithium Project as reported in the Definitive Feasibility Study (the "DFS"); discrepancies between actual and estimated mineral reserves and mineral resources, between actual and estimated development and operating costs, and between estimated and actual production; results from ongoing geotechnical analysis of projects; business conditions in Brazil; general economic conditions, geopolitical events, and regulatory changes; availability of capital; Atlas Lithium's ability to maintain its competitive position; manipulative attempts by short sellers to drive down our stock price; and dependence on key management.Additional risks related to the Company and its subsidiaries are more fully discussed in the section entitled "Risk Factors" in the Company's Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 28, 2025, and in the Company's Form 10-Q filed with the SEC on August 4, 2025. Please also refer to the Company's other filings with the SEC, all of which are available at www.sec.gov. In addition, any forward-looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements.Investor RelationsGary GuytonVice President, Investor Relations+1 (833) 661-7900 gary.guyton@atlas-lithium.comhttps://www.atlas-lithium.com/@Atlas_LithiumTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/261106 Copyright 2025 ACN Newswire via SeaPRwire.com.